Actively Recruiting

Phase Not Applicable
Age: 40Years +
All Genders
NCT04664491

Effects of COPD Standardized Management on COPD Exacerbation

Led by China-Japan Friendship Hospital · Updated on 2025-05-31

3456

Participants Needed

1

Research Sites

216 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

This is a multi-center, parallel-group,cluster randomised trial involving secondary hospitals across China. The objective is to evaluate the effect of COPD on reducing moderate-to-severe exacerbations during 12 months follow-up in primary-level medical institutions.

CONDITIONS

Official Title

Effects of COPD Standardized Management on COPD Exacerbation

Who Can Participate

Age: 40Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  1. Aged ≥40 years
  2. Post-bronchodilator FEV1/FVC <70%
  3. Baseline CAT score ≥10 or history of exacerbation in previous 12 months, defined as any use of oral antibiotics and/or oral or nebulized corticosteroids for increased cough, sputum and dyspnea, or exacerbation requiring hospitalization/ emergency admission.
  4. Local residents who live nearby and can be followed up throughout study period
  5. Written informed consent
Not Eligible

You will not qualify if you...

  1. Pregnancy, breastfeeding, or potential pregnancy
  2. Primary diagnosis of asthma
  3. Having severe cognitive dysfunction
  4. Severely ill with less than 12-month life expectancy
  5. Patients with alcohol abuse history are excluded as alcoholic individuals may have low adherence to the study. Alcohol abuse is defined as an average alcohol intake >80 g per day within recent two weeks, or daily intake of ≥40 g alcohol in men, and ≥20 g alcohol in women for more than 5 years.
  6. Have participated in similar trials or are undergoing other clinical trials
  7. Refuses or unable to give informed consent
  8. Plan to move
  9. Contraindicated to maintenance medicine.
  10. Unstable cardiovascular conditions (e.g., angina, myocardial infarction, ascending aortic aneurysm) that may prevent patients performing spirometry.
  11. Relative contraindications to spirometry, including current pneumothorax or planning to undergo thoracic/abdominal, ophthalmic or brain surgeries within next 6 months.
  12. Comorbid lung disease including bronchiectasis and tuberculosis, or undergoing anti-tuberculosis treatment
  13. Recent exacerbation treated with antibiotics and/or oral or nebulized corticosteroids within 30 days prior to enrolment.
  14. Exacerbation requiring emergency admission or hospitalization within 30 days prior to enrolment.

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

China-Japan Friendship Hospital

Beijing, Beijing Municipality, China, 100029

Actively Recruiting

Loading map...

Research Team

T

Ting Yang, MD, Ph.D

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

PREVENTION

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here